Waverly Advisors LLC Has $11.20 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Waverly Advisors LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,523 shares of the medical research company's stock after buying an additional 1,346 shares during the quarter. Waverly Advisors LLC's holdings in Thermo Fisher Scientific were worth $11,197,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Cypress Advisory Group LLC acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $253,000. Intact Investment Management Inc. lifted its holdings in Thermo Fisher Scientific by 34.0% during the 4th quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after buying an additional 660 shares in the last quarter. Purkiss Capital Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $1,121,000. Clear Harbor Asset Management LLC raised its position in shares of Thermo Fisher Scientific by 10.4% during the fourth quarter. Clear Harbor Asset Management LLC now owns 13,418 shares of the medical research company's stock worth $6,981,000 after acquiring an additional 1,269 shares during the last quarter. Finally, Fifth Third Bancorp boosted its holdings in Thermo Fisher Scientific by 11.6% in the fourth quarter. Fifth Third Bancorp now owns 335,053 shares of the medical research company's stock valued at $174,305,000 after acquiring an additional 34,917 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 1.7%

Shares of TMO traded down $6.95 during mid-day trading on Friday, hitting $393.53. 2,318,052 shares of the company's stock were exchanged, compared to its average volume of 1,865,469. The company has a market cap of $148.56 billion, a PE ratio of 23.81, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The company has a 50-day simple moving average of $445.10 and a 200 day simple moving average of $506.39. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company's quarterly revenue was up .2% on a year-over-year basis. During the same period in the prior year, the business posted $5.11 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.44%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on TMO shares. Scotiabank cut their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Evercore ISI reduced their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday. Royal Bank of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $607.43.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.